Condition: Polycythemia Vera · Sponsor: Italfarmaco
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
This description comes directly from the study's public registry record.
Maurizio Caserini · +39 02 6443 1 · patientadvocacy@italfarmacogroup.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Not Yet Recruiting |
| Emad Ibrahim, MD, Inc | Redlands, California, United States | Recruiting |
| US Oncology Inc | Englewood, Colorado, United States | Recruiting |
| American Oncology Partners of Maryland, PA | Bethesda, Maryland, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| The Cleveland Clinic Foundation | Cleveland, Ohio, United States | Recruiting |
| Oncology Associates of Oregon, P.C. | Eugene, Oregon, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Texas Oncology (Webster) - USOR | Houston, Texas, United States | Recruiting |
| Texas Oncology-Denison Cancer Center | Sherman, Texas, United States | Recruiting |
| University of Utah - Huntsman Cancer Institute - PPDS | Salt Lake City, Utah, United States | Recruiting |
+ 78 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06093672